Esperion Therapeutics Inc. (NASDAQ:ESPR)’s share price traded up 7.4% during trading on Friday . The stock traded as high as $11.19 and last traded at $11.14, with a volume of 378,396 shares trading hands. The stock had previously closed at $10.37.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, April 6th. JMP Securities reissued a “buy” rating and issued a $67.00 target price on shares of Esperion Therapeutics in a research report on Thursday, June 16th. Lake Street Capital reduced their target price on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, June 29th. Royal Bank Of Canada cut shares of Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their target price for the company from $30.00 to $15.00 in a research report on Wednesday, June 29th. Finally, JPMorgan Chase & Co. cut shares of Esperion Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $50.00 to $15.00 in a research report on Wednesday, June 29th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. Esperion Therapeutics has an average rating of “Hold” and a consensus target price of $26.29.

The company’s market capitalization is $251.23 million. The company has a 50-day moving average price of $14.66 and a 200-day moving average price of $16.06.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.09. Equities analysts forecast that Esperion Therapeutics Inc. will post ($3.57) EPS for the current fiscal year.

In other news, Director Mark E. Mcgovern acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The stock was bought at an average price of $10.00 per share, with a total value of $50,000.00. Following the acquisition, the director now owns 600 shares in the company, valued at approximately $6,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Timothy M. Mayleben acquired 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 4th. The stock was purchased at an average cost of $14.85 per share, with a total value of $103,950.00. Following the acquisition, the chief executive officer now owns 41,614 shares in the company, valued at approximately $617,967.90. The disclosure for this purchase can be found here.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.